IT1272990B - "composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione". - Google Patents
"composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione".Info
- Publication number
- IT1272990B IT1272990B ITRM940322A ITRM940322A IT1272990B IT 1272990 B IT1272990 B IT 1272990B IT RM940322 A ITRM940322 A IT RM940322A IT RM940322 A ITRM940322 A IT RM940322A IT 1272990 B IT1272990 B IT 1272990B
- Authority
- IT
- Italy
- Prior art keywords
- treatment
- pharmaceutical composition
- carbazolone
- headache
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000027109 Headache disease Diseases 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
- AMLYRCOEFHJSFS-UHFFFAOYSA-N carbazol-1-one Chemical compound C1=CC=C2C3=CC=CC(=O)C3=NC2=C1 AMLYRCOEFHJSFS-UHFFFAOYSA-N 0.000 title 1
- 231100000869 headache Toxicity 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 102000035037 5-HT3 receptors Human genes 0.000 abstract 1
- 108091005477 5-HT3 receptors Proteins 0.000 abstract 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
La invenzione si riferisce ad una composizione farmaceutica per somministrazione rettale comprendente 1, 2, 3, 9-tetraidro-9-metil-3[(2-metil-1H-imidazol-1-il) metil]-4H-carbazol-4-one sotto forma di sua base libera oppure di un suo solvato farmaceuticamente accettabile come ingrediente attivo, insieme con uno o più veicoli od eccipienti farmaceuticamente accettabili.Vengono anche descritti metodi per la produzione di tali composizioni e per il loro impiego nel trattamento di condizioni mediate dall'azione di 5-idrossitriptamina in corrispondenza di 5-HT3 recettori.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939310756A GB9310756D0 (en) | 1993-05-25 | 1993-05-25 | Compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITRM940322A0 ITRM940322A0 (it) | 1994-05-24 |
| ITRM940322A1 ITRM940322A1 (it) | 1995-11-24 |
| IT1272990B true IT1272990B (it) | 1997-07-01 |
Family
ID=10736089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITRM940322A IT1272990B (it) | 1993-05-25 | 1994-05-24 | "composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione". |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US5741806A (it) |
| EP (1) | EP0700290B1 (it) |
| JP (1) | JP2965703B2 (it) |
| KR (1) | KR100297212B1 (it) |
| CN (1) | CN1106194C (it) |
| AP (1) | AP544A (it) |
| AT (1) | ATE183643T1 (it) |
| AU (1) | AU680918B2 (it) |
| BE (1) | BE1007158A3 (it) |
| BR (1) | BR1100046A (it) |
| CA (1) | CA2162919C (it) |
| CO (1) | CO4230094A1 (it) |
| CY (1) | CY2411B1 (it) |
| CZ (1) | CZ291041B6 (it) |
| DE (1) | DE69420266T2 (it) |
| DK (1) | DK0700290T3 (it) |
| EC (1) | ECSP941088A (it) |
| ES (1) | ES2136198T3 (it) |
| FR (1) | FR2705569B1 (it) |
| GB (2) | GB9310756D0 (it) |
| GR (1) | GR3031669T3 (it) |
| HR (2) | HRP940315B1 (it) |
| HU (1) | HU227121B1 (it) |
| IE (1) | IE80632B1 (it) |
| IL (1) | IL109749A (it) |
| IS (1) | IS1868B (it) |
| IT (1) | IT1272990B (it) |
| MY (1) | MY111445A (it) |
| NO (1) | NO306448B1 (it) |
| NZ (1) | NZ267415A (it) |
| PE (1) | PE13395A1 (it) |
| PL (1) | PL175578B1 (it) |
| RU (1) | RU2132684C1 (it) |
| SA (1) | SA94150003B1 (it) |
| SG (1) | SG48119A1 (it) |
| SI (1) | SI0700290T1 (it) |
| WO (1) | WO1994027599A1 (it) |
| ZA (1) | ZA943593B (it) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200103056T2 (tr) * | 1998-06-15 | 2002-06-21 | Sepracor Inc. | Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı. |
| IL140117A0 (en) | 1998-06-15 | 2002-02-10 | Sepracor Inc | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders |
| EP1468685A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| EP1464333A3 (en) * | 1998-06-15 | 2004-12-15 | Sepracor Inc. | Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
| US6362202B1 (en) | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| US6353005B1 (en) | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
| WO2002011676A2 (en) * | 2000-08-04 | 2002-02-14 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU88268I2 (it) * | 1984-01-25 | 1994-02-03 | ||
| US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8627909D0 (en) * | 1986-11-21 | 1986-12-31 | Glaxo Group Ltd | Medicaments |
| GB8816187D0 (en) * | 1988-07-07 | 1988-08-10 | Glaxo Group Ltd | Medicaments |
| GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
| US5166145A (en) * | 1990-09-10 | 1992-11-24 | Alza Corporation | Antiemetic therapy |
-
1993
- 1993-05-25 GB GB939310756A patent/GB9310756D0/en active Pending
-
1994
- 1994-05-17 EC EC1994001088A patent/ECSP941088A/es unknown
- 1994-05-17 GB GB9409835A patent/GB2279008B/en not_active Expired - Lifetime
- 1994-05-17 SG SG1996007139A patent/SG48119A1/en unknown
- 1994-05-19 IS IS4168A patent/IS1868B/is unknown
- 1994-05-20 MY MYPI94001305A patent/MY111445A/en unknown
- 1994-05-23 CO CO94021615A patent/CO4230094A1/es unknown
- 1994-05-23 IE IE940420A patent/IE80632B1/en not_active IP Right Cessation
- 1994-05-23 AP APAP/P/1994/000643A patent/AP544A/en active
- 1994-05-23 HR HR940315A patent/HRP940315B1/xx not_active IP Right Cessation
- 1994-05-23 PE PE1994242905A patent/PE13395A1/es not_active IP Right Cessation
- 1994-05-24 WO PCT/EP1994/001652 patent/WO1994027599A1/en not_active Ceased
- 1994-05-24 CN CN94192243A patent/CN1106194C/zh not_active Expired - Lifetime
- 1994-05-24 CZ CZ19953085A patent/CZ291041B6/cs not_active IP Right Cessation
- 1994-05-24 JP JP7500204A patent/JP2965703B2/ja not_active Expired - Lifetime
- 1994-05-24 ES ES94918355T patent/ES2136198T3/es not_active Expired - Lifetime
- 1994-05-24 FR FR9406252A patent/FR2705569B1/fr not_active Expired - Lifetime
- 1994-05-24 IT ITRM940322A patent/IT1272990B/it active IP Right Grant
- 1994-05-24 HU HU9503375A patent/HU227121B1/hu unknown
- 1994-05-24 ZA ZA943593A patent/ZA943593B/xx unknown
- 1994-05-24 AT AT94918355T patent/ATE183643T1/de active
- 1994-05-24 RU RU95122578A patent/RU2132684C1/ru active
- 1994-05-24 US US08/537,950 patent/US5741806A/en not_active Expired - Lifetime
- 1994-05-24 NZ NZ267415A patent/NZ267415A/en not_active IP Right Cessation
- 1994-05-24 AU AU69709/94A patent/AU680918B2/en not_active Expired
- 1994-05-24 PL PL94311721A patent/PL175578B1/pl unknown
- 1994-05-24 EP EP94918355A patent/EP0700290B1/en not_active Expired - Lifetime
- 1994-05-24 KR KR1019950705280A patent/KR100297212B1/ko not_active Expired - Lifetime
- 1994-05-24 DE DE69420266T patent/DE69420266T2/de not_active Expired - Lifetime
- 1994-05-24 DK DK94918355T patent/DK0700290T3/da active
- 1994-05-24 SI SI9430263T patent/SI0700290T1/xx unknown
- 1994-05-24 IL IL10974994A patent/IL109749A/en not_active IP Right Cessation
- 1994-05-24 CA CA002162919A patent/CA2162919C/en not_active Expired - Lifetime
- 1994-05-24 BE BE9400528A patent/BE1007158A3/fr not_active IP Right Cessation
- 1994-06-12 SA SA94150003A patent/SA94150003B1/ar unknown
-
1995
- 1995-11-24 NO NO954783A patent/NO306448B1/no not_active IP Right Cessation
-
1996
- 1996-09-19 BR BR1100046-5A patent/BR1100046A/pt active IP Right Grant
-
1997
- 1997-06-09 HR HR970315A patent/HRP970315A2/hr not_active Application Discontinuation
-
1999
- 1999-10-27 GR GR990402759T patent/GR3031669T3/el unknown
-
2000
- 2000-06-06 CY CY0000022A patent/CY2411B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20031370L (no) | Höy afinitets småmolekyl C5A reseptor modulatorer | |
| AR027548A1 (es) | Derivados de amino pirazol utiles para el tratamiento de la obesidad y otros desordenes | |
| MXPA04002379A (es) | Compuestos novedosos. | |
| BG104877A (en) | N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders | |
| EE04911B1 (et) | Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks | |
| CY1105931T1 (el) | Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| CA2205546A1 (en) | Oral compositions containing ondansetron | |
| HUP0103203A2 (hu) | Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| SE0102055D0 (sv) | New Compounds | |
| IT1272990B (it) | "composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione". | |
| ATE305921T1 (de) | Neue analoga von 16-hydroxyeicosatetraensäure | |
| IT1261471B (it) | Composizione farmaceutica per somministrazione rettale nel trattamentodi cefalea e relativo metodo di preparazione ed impiego. | |
| DK0808303T3 (da) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreceptorantagonister | |
| ATE110379T1 (de) | Therapeutisch aktive substituierte benzimidazole und verfahren zu ihrer herstellung. | |
| AU2001290480A1 (en) | Cyclized benzamide neurokinin antagonists for use in therapy | |
| PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
| BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
| EA199901116A1 (ru) | Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион | |
| RU94046380A (ru) | Сульфатная соль замещенного триазола, способ ее получения, фармацевтические композиции на ее основе и способы их получения, способ профилактики и лечения | |
| MX9800620A (es) | (r)-5-bromo-n-(1-etil-4-metilhexahidro-1h-1,4-diazepin-6-il- 2-metoxi-6-metilamino-3-piridincarboxamida, proceso para preparacion del mismo y composicion farmaceutica que contiene tal compuesto. | |
| AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
| DE60318716D1 (de) | Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren | |
| SE0002353D0 (sv) | New use | |
| RU94045838A (ru) | Способы получения 4-пиридил и 4-пиперидинилимидазолов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted | ||
| TA | Fee payment date (situation as of event date), data collected since 19931001 |
Effective date: 19970530 |